Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a randomized, four-way crossover alcohol-interaction study in healthy male and female moderate drinkers with Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Topline results from this clinical study demonstrated that Egalet-002 did not dose dump or rapidly release the drug in a shorter period of time after being administered with different concentrations of alcohol.
With almost 30% of individuals living with chronic pain using alcohol to alleviate pain, it is important that extended release opioids do not dose dump when used in the presence of alchohol. The primary objective of the study was to evaluate the effect of alcohol administration in varying concentrations on the pharmacokinetic (PK) parameters of an 80 mg dose of Egalet-002 under naltrexone blockade. This study was conducted to characterize the effects of alcohol on Egalet-002, an important safety issue that must be evaluated for an extended-release, long acting opioid product in development.
"Given that individuals who are prescribed opioids to treat their chronic pain may also consume alcohol at the same time, it is important that there is no significant interaction with alcohol for an extended-release opioid product," said Jeff Dayno, MD, chief medical officer. "The fact that dose dumping does not occur with Egalet-002 in the presence of alcohol provides further evidence of the robustness of Egalet's Guardian™ Technology and further differentiates it from some other opioids which have a black box warning in their label regarding alcohol dose dumping."
The study examined Cmax, the maximum concentration of a drug, Tmax, the time to maximum plasma concentration, and AUC, the area under the concentration curve, in the Egalet-002 plus 4%, 20% and 40% alcohol arms compared to the Egalet-002 plus water arm. There was no evidence of alcohol dose dumping based on the mean ratios of Cmax and AUC derived from the Egalet-002 plus water arm compared to the Egalet-002 plus alcohol arms. There was also no difference in the median Tmax values between any of the treatment arms.
Guardian™ Technology
Egalet's Guardian Technology was developed to deliver commonly abused prescription medications in an abuse-deterrent form. The unique plastic injection molding manufacturing process results in abuse-deterrent features designed to resist the most common methods, as well as more rigorous methods, of abuse for morphine and oxycodone -- injection and snorting, respectively. The Guardian Technology can be applied broadly across different classes of pharmaceutical products. Egalet's two lead abuse-deterrent product candidates, Egalet-001 and Egalet-002, are oral formulations of morphine and oxycodone, respectively, developed with the Guardian Technology to make particle size reduction difficult and resist dissolution. They are in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
Weight loss drug semaglutide may offer relief for knee arthritis pain